Literature DB >> 15669772

Assessment of drug interactions relevant to pharmacodynamic indirect response models.

Justin Earp1, Wojciech Krzyzanski, Abhijit Chakraborty, Miren K Zamacona, William J Jusko.   

Abstract

The assessment of drug interactions for a simple turnover system when the basic pharmacodynamic response is governed by indirect mechanisms was explored. This report describes a diverse array of possible in vivo pharmacodynamic effects from a combination of two drugs acting by similar or different indirect mechanisms. Various conditions of pharmacodynamic drug combinations were explored mathematically and by simulation: (a) interactions of two drugs acting simultaneously either on the production (k(in)) or on the dissipation (k(out)) processes controlling the in vivo response by competitive (four cases) or non-competitive interaction (six cases); and (b) combinations of two drugs acting on separate k(in) and k(out) processes simultaneously (four cases). A range of different combinations of drug doses was used. Plasma concentration time profiles were generated according to monoexponential disposition. Pharmacodynamic response profiles were simulated using the above conditions and characterized by descriptors such as Area Between Effect (and Baseline) Curve (ABEC) values. The interaction of agents by competitive mechanisms produced net responses that were additive in nature. Response profiles for non-competitive interactions on the same process were both antagonistic (for two drugs with effects that oppose each other) and synergistic (for two drugs that produce the same response). On the other hand, response signatures for agents acting non-competitively on the production and dissipation factors by opposing mechanisms (e.g. inhibiting k(in) plus stimulating k(out)) showed dramatic changes in net effects and produced apparent drug synergy. Net indirect response profiles for joint use of two or more drugs measured by ABEC values may look "additive", "antagonistic", or "synergistic" depending on doses, their intrinsic potencies, the nature of interaction (competitive or non-competitive) as well as their mechanisms of action. These models may help explain changes in pharmacologic responses to two agents in a more rational and mechanistic fashion than older empirical methods.

Mesh:

Substances:

Year:  2004        PMID: 15669772     DOI: 10.1007/s10928-004-8319-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  22 in total

Review 1.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

2.  Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.

Authors:  Emilie A G Molins; William J Jusko
Journal:  AAPS J       Date:  2018-06-27       Impact factor: 4.009

Review 3.  Assessment of non-linear combination effect terms for drug-drug interactions.

Authors:  Gilbert Koch; Johannes Schropp; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-16       Impact factor: 2.745

4.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.

Authors:  Santosh Kumar Puttrevu; Rachumallu Ramakrishna; Manisha Bhateria; Moon Jain; Kashif Hanif; Rabi Sankar Bhatta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

5.  Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.

Authors:  Ruihong Yu; Dawei Song; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

6.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

7.  Interactions of everolimus and sorafenib in pancreatic cancer cells.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Wen W Ma; William J Jusko
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

8.  Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

9.  Mechanism-based pharmacodynamic modeling.

Authors:  Melanie A Felmlee; Marilyn E Morris; Donald E Mager
Journal:  Methods Mol Biol       Date:  2012

10.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism: the interaction between tramadol and its active metabolite on micro-opioid agonism and monoamine reuptake inhibition, in the rat.

Authors:  Horst Beier; María J Garrido; Thomas Christoph; Dirk Kasel; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2007-11-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.